Literature DB >> 16055882

Standardisation of spirometry.

M R Miller1, J Hankinson, V Brusasco, F Burgos, R Casaburi, A Coates, R Crapo, P Enright, C P M van der Grinten, P Gustafsson, R Jensen, D C Johnson, N MacIntyre, R McKay, D Navajas, O F Pedersen, R Pellegrino, G Viegi, J Wanger.   

Abstract

Mesh：

Year:  2005        PMID： 16055882     DOI： 10.1183/09031936.05.00034805

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  2000 in total

1.  The Accuracy of an Ambulatory Level III Sleep Study Compared to a Level I Sleep Study for the Diagnosis of Sleep-Disordered Breathing in Children With Neuromuscular Disease.

Authors:  Haley Fishman; Colin Massicotte; Rhonda Li; Weeda Zabih; Laura C McAdam; Suhail Al-Saleh; Reshma Amin
Journal:  J Clin Sleep Med       Date:  2018-12-15       Impact factor: 4.062

2.  Objectively Measured Disrupted Sleep Is Independently and Directly Associated With Low Exercise Capacity in Males: A Structural Equation Model.

Authors:  Ren-Jing Huang; Shin-Da Lee; Ching-Hsiang Lai; Shen-Wen Chang; Ai-Hui Chung; Chiung-Wei Chen; I-Ning Huang; Hua Ting
Journal:  J Clin Sleep Med       Date:  2018-12-15       Impact factor: 4.062

3.  Correlation of pulmonary hypertension severity with metrics of comorbid sleep-disordered breathing.

Authors:  Douglas L Prisco; Anthony L Sica; Arunabh Talwar; Mangala Narasimhan; Kennedy Omonuwa; Babak Hakimisefat; Sophy Dedopoulos; Nawid Shakir; Harly Greenberg
Journal:  Sleep Breath       Date:  2010-10-07       Impact factor: 2.816

4.  Acute volume loading exacerbates direct ventricular interaction in a model of COPD.

Authors:  William S Cheyne; Alexandra M Williams; Megan I Harper; Neil D Eves
Journal:  J Appl Physiol (1985)       Date:  2017-07-20

5.  Fat-free mass depletion in patients with COPD in Brazil: development of a new cutoff point and its relation with mortality and extrapulmonary manifestations.

Authors:  A Travassos; A Rodrigues; K C Furlanetto; L Donária; G W Bisca; A G Nellessen; F Pitta; N A Hernandes
Journal:  Eur J Clin Nutr       Date:  2017-07-19       Impact factor: 4.016

6.  Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults.

Authors:  Sandy S Chang; Shu Chen; Gail J McAvay; Mary E Tinetti
Journal:  J Am Geriatr Soc       Date:  2012-10-04       Impact factor: 5.562

7.  Acute changes in lung function following controlled exposure to cookstove air pollution in the subclinical tests of volunteers exposed to smoke (STOVES) study.

Authors:  Kristen M Fedak; Nicholas Good; Ethan S Walker; John Balmes; Robert D Brook; Maggie L Clark; Tom Cole-Hunter; Robert Devlin; Christian L'Orange; Gary Luckasen; John Mehaffy; Rhiannon Shelton; Ander Wilson; John Volckens; Jennifer L Peel
Journal:  Inhal Toxicol       Date:  2020-04-16       Impact factor: 2.724

8.  Quantitative and semiquantitative measures of regional pulmonary microvascular perfusion by magnetic resonance imaging and their relationships to global lung perfusion and lung diffusing capacity: the multiethnic study of atherosclerosis chronic obstructive pulmonary disease study.

Authors:  Katja Hueper; Megha A Parikh; Martin R Prince; Christian Schoenfeld; Chia Liu; David A Bluemke; Stephen M Dashnaw; Thomas A Goldstein; Eric A Hoffman; Joao A Lima; Jan Skrok; Jie Zheng; R Graham Barr; Jens Vogel-Claussen
Journal:  Invest Radiol       Date:  2013-04       Impact factor: 6.016

9.  Methacholine PC20 in African Americans and whites with asthma with homozygous genotypes at ADRB2 codon 16.

Authors:  Kathryn Blake; James D Cury; Jobayer Hossain; Kelan Tantisira; Jianwei Wang; Edward Mougey; John Lima
Journal:  Pulm Pharmacol Ther       Date:  2013-02-04       Impact factor: 3.410

10.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.